Summary

Treatment with tocilizumab, a humanized monoclonal antibody that interrupts interleukin-6-mediated signaling, results in meaningful improvement of polyarticular-course juvenile idiopathic arthritis following methotrexate failure, with treatment responses maintained to at least 40 weeks. This article discusses findings from the A Study of Tocilizumab in Patients with Active Polyarticular-Course Juvenile Idiopathic Arthritis [CHERISH; NCT00988221] trial.